Ipolipid is a lipid-regulating agent which lowers elevated serum lipids primarily by decreasing serum triglyceride with a variable reduction in total serum cholesterol.
These decreases occur primarily in the very low-density lipoprotein (VLDL) fractions and less frequently in the low-density lipoprotein (LDL) fraction. In addition, Ipolipid increases the high-density lipoprotein (HDL). The mechanism of action is not clear.
Ipolipid is well absorbed by oral route. Peak plasma levels occur in 1-2 hrs after oral administration with a plasma t½ of 1.5 hrs following single dose.